Literature DB >> 6428310

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.

H Giamarellou, N P Zissis, G Tagari, J Bouzos.   

Abstract

The in vitro interactions between amikacin, netilmicin, tobramycin, gentamicin, and various antipseudomonal beta-lactams were studied by the agar dilution checkerboard technique against 30 Pseudomonas aeruginosa strains resistant to all tested antibiotics. Amikacin produced more frequent synergy both at the total and clinically applicable level. Among the beta-lactams, clinically relevant synergistic interactions were obtained in the following order: ceftazidime and ceftriaxone greater than moxalactam greater than aztreonam greater than cefotaxime greater than azlocillin greater than cefoperazone greater than cefsulodin greater than carbenicillin.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6428310      PMCID： PMC185575          DOI： 10.1128/AAC.25.4.534

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Clinical efficacy of aminoglycosides: an example of balance between microbiology and pharmacology.

Authors:  J Klastersky
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

2.  Antibiotics of choice in suspected serious sepsis.

Authors:  S Levin
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

3.  Mechanisms of resistance to aminoglycosides.

Authors:  J Davies; P Courvalin
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

4.  Significance of antimicrobial synergism for the outcome of gram negative sepsis.

Authors:  J Klastersky; F Meunier-Carpentier; J M Prevost
Journal:  Am J Med Sci       Date:  1977 Mar-Apr       Impact factor: 2.378

5.  Pseudomonas bacteremia. Review of 108 cases.

Authors:  M R Flick; L E Cluff
Journal:  Am J Med       Date:  1976-04       Impact factor: 4.965

6.  Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.

Authors:  R D Meyer; R P Lewis; J Halter; M White
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

7.  Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.

Authors:  L Mintz; W L Drew
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

8.  Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.

Authors:  T O Kurtz; D J Winston; D A Bruckner; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

9.  Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis.

Authors:  J Klastersky
Journal:  Infection       Date:  1980       Impact factor: 3.553

10.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191
View more
  21 in total

1.  Pairwise antibiotic interactions in Escherichia coli: triclosan, rifampicin and aztreonam with nine other classes of antibiotics.

Authors:  Caroline Nguyen; Alice Zhou; Ayesha Khan; Jeffrey H Miller; Pamela Yeh
Journal:  J Antibiot (Tokyo)       Date:  2016-03-09       Impact factor: 2.649

2.  Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.

Authors:  L Leibovici; M Paul; O Poznanski; M Drucker; Z Samra; H Konigsberger; S D Pitlik
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

4.  Species-specific activity of antibacterial drug combinations.

Authors:  Ana Rita Brochado; Anja Telzerow; Jacob Bobonis; Manuel Banzhaf; André Mateus; Joel Selkrig; Emily Huth; Stefan Bassler; Jordi Zamarreño Beas; Matylda Zietek; Natalie Ng; Sunniva Foerster; Benjamin Ezraty; Béatrice Py; Frédéric Barras; Mikhail M Savitski; Peer Bork; Stephan Göttig; Athanasios Typas
Journal:  Nature       Date:  2018-07-04       Impact factor: 49.962

5.  Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections.

Authors:  G Satta; G Cornaglia; G Foddis; R Pompei
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 6.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

7.  Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.

Authors:  A Pefanis; H Giamarellou; P Karayiannakos; I Donta
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 8.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.

Authors:  Mical Paul; Karla Soares-Weiser; Leonard Leibovici
Journal:  BMJ       Date:  2003-05-24

Review 9.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.

Authors:  Mical Paul; Ishay Benuri-Silbiger; Karla Soares-Weiser; Leonard Leibovici
Journal:  BMJ       Date:  2004-03-02

10.  Interactions of Ceftazidime and Amikacin on Multiresistant Pseudomonas aeruginosa: Have They Altered in the Six-Year Period from 1988 to 1994?

Authors:  E J Giamarellos-Bourboulis; A Pefanis; P Grecka; K Kanellakopoulou; H Giamarellou
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.